Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10

Rhea-AI Summary

Eyenovia, Inc. will release its financial results for Q2 2023 on August 10, 2023. The company is an ophthalmic technology company that commercializes Mydcombi™ and develops the Optejet® device for various therapeutic product candidates. Eyenovia will host an investor conference call and webcast at 4:30pm EDT to review the financial and operating results. The call can be accessed by dialing 1-877-407-9039 (domestic) or 1-201-689-8470 (international) using conference ID 13739696. A live webcast will be available on Eyenovia's investor relations page.

Company to host an investor conference call and webcast at 4:30pm EDT

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the Company will release financial results for the second quarter ended June 30, 2023 on Thursday, August 10, 2023, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. EDT to review the financial and operating results.

Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and referencing conference ID 13739696.

To access the Call me™ feature, which avoids having to wait for an operator, click here.

A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide + phenylephrine ophthalmic spray) for mydriasis, as well as the ongoing late-stage development of medications in the Optejet device for presbyopia and myopia progression (partnered with Bausch+Lomb). For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

FAQ

When will Eyenovia release its financial results for Q2 2023?

Eyenovia will release its financial results for Q2 2023 on August 10, 2023.

What is Eyenovia known for?

Eyenovia is an ophthalmic technology company that commercializes Mydcombi™ and develops the Optejet® device for various therapeutic product candidates.

What is the purpose of the investor conference call and webcast?

The investor conference call and webcast will be hosted by Eyenovia to review the financial and operating results.

How can participants access the conference call?

Participants can access the conference call by dialing 1-877-407-9039 (domestic) or 1-201-689-8470 (international) using conference ID 13739696.

Where can the live webcast be accessed?

The live webcast can be accessed on Eyenovia's investor relations page on their corporate website.